Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Hyundai Bioscience Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩19,530.00 |
52 Week High | ₩41,200.00 |
52 Week Low | ₩16,700.00 |
Beta | 1.12 |
11 Month Change | 6.31% |
3 Month Change | -3.56% |
1 Year Change | -19.46% |
33 Year Change | -36.38% |
5 Year Change | 62.75% |
Change since IPO | 68.36% |
Recent News & Updates
Recent updates
The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About
Mar 14Is Hyundai Bioscience (KOSDAQ:048410) Using Too Much Debt?
Feb 07Imagine Holding Hyundai Bioscience (KOSDAQ:048410) Shares While The Price Zoomed 439% Higher
Jan 03The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About
Nov 29Shareholder Returns
A048410 | KR Personal Products | KR Market | |
---|---|---|---|
7D | 15.8% | 2.6% | -0.04% |
1Y | -19.5% | 28.8% | 2.2% |
Return vs Industry: A048410 underperformed the KR Personal Products industry which returned 28.8% over the past year.
Return vs Market: A048410 underperformed the KR Market which returned 2.2% over the past year.
Price Volatility
A048410 volatility | |
---|---|
A048410 Average Weekly Movement | 4.6% |
Personal Products Industry Average Movement | 7.6% |
Market Average Movement | 4.9% |
10% most volatile stocks in KR Market | 11.1% |
10% least volatile stocks in KR Market | 2.2% |
Stable Share Price: A048410 has not had significant price volatility in the past 3 months.
Volatility Over Time: A048410's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 63 | Jong-Won Choi | www.hyundaibioscience.com |
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19.
Hyundai Bioscience Co., Ltd. Fundamentals Summary
A048410 fundamental statistics | |
---|---|
Market cap | ₩777.67b |
Earnings (TTM) | -₩11.22b |
Revenue (TTM) | ₩11.37b |
68.4x
P/S Ratio-69.3x
P/E RatioIs A048410 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A048410 income statement (TTM) | |
---|---|
Revenue | ₩11.37b |
Cost of Revenue | ₩5.38b |
Gross Profit | ₩5.99b |
Other Expenses | ₩17.20b |
Earnings | -₩11.22b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -281.70 |
Gross Margin | 52.66% |
Net Profit Margin | -98.67% |
Debt/Equity Ratio | 11.6% |
How did A048410 perform over the long term?
See historical performance and comparison